Fig. 4From: PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylationTrametinib can suppress the increases in the migration and invasion capabilities of pNETs induced by PTEN loss. A The relative migration and invasion abilities of and ERK phosphorylation status in QGP-1 cells with (shPTEN) and without (shLuc) knockdown of PTEN and with (shPTEN + trametinib) and without trametinib treatment. Migration: shPTEN vs. shPTEN + trametinib, P = 0.030; Wilcoxon rank-sum test. Invasion: shPTEN vs. shPTEN + trametinib, P = 0.030; Wilcoxon rank-sum test. B The relative migration and invasion abilities of and ERK phosphorylation status in NIT-1 cells with (shPTEN) and without (shLuc) knockdown of PTEN and with (shPTEN + trametinib) and without trametinib treatment. Migration: shPTEN vs. shPTEN + trametinib, P = 0.029; Wilcoxon rank-sum test. Invasion: shPTEN vs. shPTEN + trametinib, P = 0.030; Wilcoxon rank-sum testBack to article page